KR20140053843A - 나노입자 전달 시스템, 이의 제조 및 용도 - Google Patents

나노입자 전달 시스템, 이의 제조 및 용도 Download PDF

Info

Publication number: KR20140053843A
Authority: KR; South Korea
Prior art keywords: nanoparticles; nanoparticle; liposomes; liposome; thermosensitive
Prior art date: 2011-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020137023246A

Other languages

English (en)

Korean (ko)

Inventor

아그네스 뽀띠에

로랭 레비

마리-에디뜨 메이르

마띠유 제르맹

Original Assignee

나노비오?스

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-31

Filing date

2012-01-31

Publication date

2014-05-08

2012-01-31 Application filed by 나노비오?스 filed Critical 나노비오?스

2014-05-08 Publication of KR20140053843A publication Critical patent/KR20140053843A/ko

Status Withdrawn legal-status Critical Current

Links

239000002105 nanoparticle Substances 0.000 title claims abstract description 195
238000012384 transportation and delivery Methods 0.000 title description 14
238000002360 preparation method Methods 0.000 title description 6
239000002502 liposome Substances 0.000 claims abstract description 156
239000000203 mixture Substances 0.000 claims abstract description 40
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 52
238000000034 method Methods 0.000 claims description 44
206010028980 Neoplasm Diseases 0.000 claims description 40
150000002632 lipids Chemical class 0.000 claims description 32
239000012528 membrane Substances 0.000 claims description 32
230000001225 therapeutic effect Effects 0.000 claims description 27
235000012000 cholesterol Nutrition 0.000 claims description 26
239000003795 chemical substances by application Substances 0.000 claims description 25
230000008685 targeting Effects 0.000 claims description 25
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 17
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 16
102000004169 proteins and genes Human genes 0.000 claims description 15
108090000623 proteins and genes Proteins 0.000 claims description 15
230000007704 transition Effects 0.000 claims description 15
239000000725 suspension Substances 0.000 claims description 14
239000000032 diagnostic agent Substances 0.000 claims description 13
229940039227 diagnostic agent Drugs 0.000 claims description 13
229940124597 therapeutic agent Drugs 0.000 claims description 13
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
239000012736 aqueous medium Substances 0.000 claims description 12
-1 succinimidyl Chemical group 0.000 claims description 9
239000003446 ligand Substances 0.000 claims description 8
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims description 6
150000007942 carboxylates Chemical group 0.000 claims description 6
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
229910000077 silane Inorganic materials 0.000 claims description 6
239000000427 antigen Substances 0.000 claims description 5
108091007433 antigens Proteins 0.000 claims description 5
102000036639 antigens Human genes 0.000 claims description 5
230000008878 coupling Effects 0.000 claims description 5
238000010168 coupling process Methods 0.000 claims description 5
238000005859 coupling reaction Methods 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 4
150000001412 amines Chemical group 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
108010038807 Oligopeptides Proteins 0.000 claims description 3
102000015636 Oligopeptides Human genes 0.000 claims description 3
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 3
102000003675 cytokine receptors Human genes 0.000 claims description 3
108010057085 cytokine receptors Proteins 0.000 claims description 3
239000005556 hormone Substances 0.000 claims description 3
229940088597 hormone Drugs 0.000 claims description 3
108091008039 hormone receptors Proteins 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
239000007791 liquid phase Substances 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims description 3
102000039446 nucleic acids Human genes 0.000 claims description 3
150000007523 nucleic acids Chemical class 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
229920001184 polypeptide Polymers 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
125000004185 ester group Chemical group 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
150000003573 thiols Chemical class 0.000 claims description 2
150000003722 vitamin derivatives Chemical class 0.000 claims description 2
238000000733 zeta-potential measurement Methods 0.000 claims description 2
235000021317 phosphate Nutrition 0.000 claims 2
150000003013 phosphoric acid derivatives Chemical group 0.000 claims 1
230000036541 health Effects 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 50
229940031182 nanoparticles iron oxide Drugs 0.000 description 25
239000000243 solution Substances 0.000 description 25
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 24
239000012071 phase Substances 0.000 description 23
238000000576 coating method Methods 0.000 description 21
239000000463 material Substances 0.000 description 21
201000011510 cancer Diseases 0.000 description 19
210000001519 tissue Anatomy 0.000 description 18
239000002245 particle Substances 0.000 description 17
230000005291 magnetic effect Effects 0.000 description 15
239000000126 substance Substances 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
238000011282 treatment Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000011248 coating agent Substances 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
239000002609 medium Substances 0.000 description 12
238000010438 heat treatment Methods 0.000 description 11
230000003993 interaction Effects 0.000 description 11
230000005865 ionizing radiation Effects 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
150000003904 phospholipids Chemical class 0.000 description 10
230000004913 activation Effects 0.000 description 9
238000001994 activation Methods 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
230000000694 effects Effects 0.000 description 9
210000000865 mononuclear phagocyte system Anatomy 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
239000012530 fluid Substances 0.000 description 8
239000002202 Polyethylene glycol Substances 0.000 description 7
229910010272 inorganic material Inorganic materials 0.000 description 7
239000011147 inorganic material Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
229910052751 metal Inorganic materials 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
230000005855 radiation Effects 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
239000000499 gel Substances 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000000696 magnetic material Substances 0.000 description 6
239000002184 metal Substances 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000010931 gold Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
239000002122 magnetic nanoparticle Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
230000008569 process Effects 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
238000004627 transmission electron microscopy Methods 0.000 description 5
108010017384 Blood Proteins Proteins 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000000232 Lipid Bilayer Substances 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
239000013078 crystal Substances 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000009503 electrostatic coating Methods 0.000 description 4
238000001125 extrusion Methods 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
150000002190 fatty acyls Chemical group 0.000 description 4
229910001448 ferrous ion Inorganic materials 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000007306 functionalization reaction Methods 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000003384 imaging method Methods 0.000 description 4
239000004973 liquid crystal related substance Substances 0.000 description 4
238000002595 magnetic resonance imaging Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
239000012429 reaction media Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000012756 surface treatment agent Substances 0.000 description 4
229910000859 α-Fe Inorganic materials 0.000 description 4
206010027476 Metastases Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
239000003012 bilayer membrane Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000002296 dynamic light scattering Methods 0.000 description 3
CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000000691 measurement method Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000003504 photosensitizing agent Substances 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
235000019982 sodium hexametaphosphate Nutrition 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
230000003068 static effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
238000007725 thermal activation Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229910052692 Dysprosium Inorganic materials 0.000 description 2
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229910052779 Neodymium Inorganic materials 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
239000004115 Sodium Silicate Substances 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
229910052769 Ytterbium Inorganic materials 0.000 description 2
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
238000002725 brachytherapy Methods 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
201000007455 central nervous system cancer Diseases 0.000 description 2
208000025997 central nervous system neoplasm Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000000604 cryogenic transmission electron microscopy Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000000799 fusogenic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
150000004679 hydroxides Chemical class 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910052809 inorganic oxide Inorganic materials 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
238000010884 ion-beam technique Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000014207 opsonization Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
238000012856 packing Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000002096 quantum dot Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000011160 research Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
229910052911 sodium silicate Inorganic materials 0.000 description 2
239000006104 solid solution Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
229910003321 CoFe Inorganic materials 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102100023471 E-selectin Human genes 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
229910052689 Holmium Inorganic materials 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
208000033724 Malignant tumor of fallopian tubes Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
229910017493 Nd 2 O 3 Inorganic materials 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108010035766 P-Selectin Proteins 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229910052777 Praseodymium Inorganic materials 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
229910052772 Samarium Inorganic materials 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
239000004974 Thermotropic liquid crystal Substances 0.000 description 1
229910052775 Thulium Inorganic materials 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
SDXDHLDNCJPIJZ-UHFFFAOYSA-N [Zr].[Zr] Chemical compound [Zr].[Zr] SDXDHLDNCJPIJZ-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012431 aqueous reaction media Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000004791 biological behavior Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000001721 carbon Chemical class 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
229910000420 cerium oxide Inorganic materials 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002800 charge carrier Substances 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
208000012191 childhood neoplasm Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
LNBHUCHAFZUEGJ-UHFFFAOYSA-N europium(3+) Chemical compound [Eu+3] LNBHUCHAFZUEGJ-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229910001447 ferric ion Inorganic materials 0.000 description 1
230000005294 ferromagnetic effect Effects 0.000 description 1
239000003302 ferromagnetic material Substances 0.000 description 1
229960002089 ferrous chloride Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940014144 folate Drugs 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
229910001938 gadolinium oxide Inorganic materials 0.000 description 1
229940075613 gadolinium oxide Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229910000449 hafnium oxide Inorganic materials 0.000 description 1
WIHZLLGSGQNAGK-UHFFFAOYSA-N hafnium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Hf+4] WIHZLLGSGQNAGK-UHFFFAOYSA-N 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229940005740 hexametaphosphate Drugs 0.000 description 1
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
OWCYYNSBGXMRQN-UHFFFAOYSA-N holmium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Ho+3].[Ho+3] OWCYYNSBGXMRQN-UHFFFAOYSA-N 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229910003443 lutetium oxide Inorganic materials 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
239000011553 magnetic fluid Substances 0.000 description 1
230000005389 magnetism Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
108091070501 miRNA Proteins 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000002679 microRNA Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002086 nanomaterial Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000011368 organic material Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
MPARYNQUYZOBJM-UHFFFAOYSA-N oxo(oxolutetiooxy)lutetium Chemical compound O=[Lu]O[Lu]=O MPARYNQUYZOBJM-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
238000001935 peptisation Methods 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
230000035699 permeability Effects 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
238000011338 personalized therapy Methods 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
238000007539 photo-oxidation reaction Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
238000013439 planning Methods 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
WXBOMIKEWRRKBB-UHFFFAOYSA-N rhenium(iv) oxide Chemical compound O=[Re]=O WXBOMIKEWRRKBB-UHFFFAOYSA-N 0.000 description 1
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
229910001954 samarium oxide Inorganic materials 0.000 description 1
229940075630 samarium oxide Drugs 0.000 description 1
FKTOIHSPIPYAPE-UHFFFAOYSA-N samarium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Sm+3].[Sm+3] FKTOIHSPIPYAPE-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000002966 stenotic effect Effects 0.000 description 1
150000003431 steroids Chemical group 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000004381 surface treatment Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
HKCRVXUAKWXBLE-UHFFFAOYSA-N terbium(3+) Chemical compound [Tb+3] HKCRVXUAKWXBLE-UHFFFAOYSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
ZIKATJAYWZUJPY-UHFFFAOYSA-N thulium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Tm+3].[Tm+3] ZIKATJAYWZUJPY-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020137023246A 2011-01-31 2012-01-31 나노입자 전달 시스템, 이의 제조 및 용도 Withdrawn KR20140053843A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161437817P	2011-01-31	2011-01-31
US61/437,817		2011-01-31
EP11305096.7		2011-01-31
EP11305096		2011-01-31
PCT/EP2012/051507 WO2012104275A2 (en)	2011-01-31	2012-01-31	Nanoparticles delivery systems, preparation and uses thereof

Publications (1)

Publication Number	Publication Date
KR20140053843A true KR20140053843A (ko)	2014-05-08

Family

ID=44202131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020137023246A Withdrawn KR20140053843A (ko)	2011-01-31	2012-01-31	나노입자 전달 시스템, 이의 제조 및 용도

Country Status (13)

Country	Link
US (1)	US9956175B2 (pl)
EP (1)	EP2670394B1 (pl)
JP (2)	JP6158714B2 (pl)
KR (1)	KR20140053843A (pl)
CN (1)	CN103429227B (pl)
AU (1)	AU2012213538A1 (pl)
CA (1)	CA2825564A1 (pl)
DK (1)	DK2670394T3 (pl)
EA (1)	EA024930B1 (pl)
IL (1)	IL227665A (pl)
PL (1)	PL2670394T3 (pl)
WO (1)	WO2012104275A2 (pl)
ZA (1)	ZA201306464B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101616465B1 (ko)	2009-11-02	2016-04-28	펄스 테라퓨틱스, 인코포레이티드	기자성 스테이터 시스템 및 마그네틱 로터의 무선제어 방법
WO2012104277A2 (en)	2011-01-31	2012-08-09	Nanobiotix	Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
PL2670394T3 (pl)	2011-01-31	2019-03-29	Nanobiotix	Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
BR112014014412A2 (pt)	2011-12-16	2017-06-13	Nanobiotix	nanopartículas compreendendo materiais metálicos e de óxido de háfnio, sua preparação e uso
WO2014074475A1 (en) *	2012-11-07	2014-05-15	Emmetrope Ophthalmics Llc	Magnetic eye shields and methods of treatment and diagnosis using the same
CA2904758A1 (en) *	2013-03-14	2014-09-25	Peroxyium, Inc., Delaware C Corp.	Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceo2 particles via nano-encapsulation and coating
JP6387400B2 (ja) *	2013-05-30	2018-09-05	ナノビオティックスＮａｎｏｂｉｏｔｉｘ	医薬組成物、その製造および使用
ES2733098T3 (es)	2014-05-06	2019-11-27	Memorial Sloan Kettering Cancer Center	Sistema portador magnetoenzimático para imagenología y transporte y liberación selectivos de agentes activos
DK3223796T3 (da)	2014-11-25	2021-09-27	Curadigm Sas	Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
HK1245086A1 (zh) *	2014-11-25	2018-08-24	Nanobiotix	处方药物组成及其制备和使用
ES2951598T3 (es)	2014-11-25	2023-10-23	Curadigm Sas	Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
WO2016083331A1 (en)	2014-11-25	2016-06-02	Nanobiotix	Pharmaceutical composition, preparation and uses thereof
KR102666251B1 (ko) *	2014-11-25	2024-05-27	큐라디즘	약학적 조성물, 이의 제조 및 용도
MA43100A (fr)	2015-05-28	2018-09-05	Nanobiotix	Nanoparticules à utiliser en tant que vaccin thérapeutique
CN105902400B (zh) *	2016-06-17	2019-10-11	四川百奥可生物科技有限责任公司	一种包裹生物酶的微粒及其制备方法和应用
EP4461363A3 (en)	2017-12-19	2025-01-08	Nanobiotix	Nanoparticles for use in enhancing brain performances or in treating stress
KR102729931B1 (ko)	2017-12-19	2024-11-13	나노비오?笭?	신경 장애의 치료에서 사용하기 위한 나노입자
US11918315B2 (en) *	2018-05-03	2024-03-05	Pulse Therapeutics, Inc.	Determination of structure and traversal of occlusions using magnetic particles
CN109387641B (zh) *	2018-12-20	2022-04-15	深圳职业技术学院	一种以磁性氧化铁纳米粒子为信号放大器检测天蚕素b的装置及检测方法
EP4069317A4 (en) *	2019-12-05	2024-04-03	The General Hospital Corporation	COMPOSITIONS AND METHODS FOR TUNEABLE MAGNETIC NANOPARTICLES
WO2023186923A1 (en)	2022-03-30	2023-10-05	Meta Materials Inc.	Implanted agent delivery system
CN115558100B (zh) *	2022-09-30	2023-12-22	桂林理工大学	一种改性透射电镜载网及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4672040A (en) *	1983-05-12	1987-06-09	Advanced Magnetics, Inc.	Magnetic particles for use in separations
US5225212A (en) *	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
WO1993026019A1 (en)	1992-06-08	1993-12-23	Molecular Bioquest, Inc.	Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
US6726925B1 (en) *	1998-06-18	2004-04-27	Duke University	Temperature-sensitive liposomal formulation
US7769423B2 (en)	2002-09-11	2010-08-03	Duke University	MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
NO329127B1 (no)	2006-09-12	2010-08-30	Epitarget As	Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no)	2006-09-22	2008-03-24	Epitarget As	T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
US20090004258A1 (en) *	2007-06-27	2009-01-01	National Health Research Institutes	Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
EP2067485A1 (en)	2007-12-07	2009-06-10	Koninklijke Philips Electronics N.V.	Drug carrier providing MRI contrast enhancement
WO2012104277A2 (en)	2011-01-31	2012-08-09	Nanobiotix	Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
PL2670394T3 (pl)	2011-01-31	2019-03-29	Nanobiotix	Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania

2012
- 2012-01-31 PL PL12702019T patent/PL2670394T3/pl unknown
- 2012-01-31 KR KR1020137023246A patent/KR20140053843A/ko not_active Withdrawn
- 2012-01-31 CA CA2825564A patent/CA2825564A1/en not_active Abandoned
- 2012-01-31 CN CN201280007205.1A patent/CN103429227B/zh not_active Expired - Fee Related
- 2012-01-31 DK DK12702019.6T patent/DK2670394T3/en active
- 2012-01-31 WO PCT/EP2012/051507 patent/WO2012104275A2/en not_active Ceased
- 2012-01-31 EP EP12702019.6A patent/EP2670394B1/en active Active
- 2012-01-31 US US13/981,757 patent/US9956175B2/en active Active
- 2012-01-31 AU AU2012213538A patent/AU2012213538A1/en not_active Abandoned
- 2012-01-31 JP JP2013550905A patent/JP6158714B2/ja active Active
- 2012-01-31 EA EA201391119A patent/EA024930B1/ru not_active IP Right Cessation
2013
- 2013-07-25 IL IL227665A patent/IL227665A/en not_active IP Right Cessation
- 2013-08-28 ZA ZA2013/06464A patent/ZA201306464B/en unknown
2017
- 2017-05-09 JP JP2017093099A patent/JP2017193550A/ja active Pending

Also Published As

Publication number	Publication date
CN103429227B (zh)	2017-12-19
JP2014510040A (ja)	2014-04-24
JP6158714B2 (ja)	2017-07-05
JP2017193550A (ja)	2017-10-26
PL2670394T3 (pl)	2019-03-29
EP2670394B1 (en)	2018-11-21
CN103429227A (zh)	2013-12-04
DK2670394T3 (en)	2019-01-14
EA024930B1 (ru)	2016-11-30
ZA201306464B (en)	2014-04-30
US20140056813A1 (en)	2014-02-27
AU2012213538A1 (en)	2013-08-15
AU2012213538A2 (en)	2013-09-26
WO2012104275A3 (en)	2012-11-01
CA2825564A1 (en)	2012-08-09
EA201391119A1 (ru)	2014-01-30
EP2670394A2 (en)	2013-12-11
WO2012104275A2 (en)	2012-08-09
IL227665A (en)	2017-03-30
IL227665A0 (en)	2013-09-30
US9956175B2 (en)	2018-05-01

Legal Events

Date	Code	Title	Description
2013-09-02	PA0105	International application	Patent event date: 20130902 Patent event code: PA01051R01D Comment text: International Patent Application
2014-05-08	PG1501	Laying open of application
2017-03-01	PC1203	Withdrawal of no request for examination
2017-03-01	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid

Publication	Publication Date	Title
EP2670394B1 (en)	2018-11-21	Nanoparticles delivery systems, preparation and uses thereof
US10064962B2 (en)	2018-09-04	Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
US10729792B2 (en)	2020-08-04	Texaphyrin-phospholipid conjugates and methods of preparing same
JP2004511426A5 (pl)	2005-02-03
JP5082446B2 (ja)	2012-11-28	被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
US20090004258A1 (en)	2009-01-01	Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
CN103446588B (zh)	2015-12-02	靶向型诊疗联用药物及其制备方法和应用
WO2020217231A2 (en)	2020-10-29	Magnetic nanosystem and method to produce the nanosystem
Jiang et al.	2023	New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment
Karathanasis et al.	2008	MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma
ES2702561T3 (es)	2019-03-01	Sistemas de aporte de nanopartículas, preparación y usos de los mismos
JP2011057591A (ja)	2011-03-24	リポソーム、並びに診断用造影剤、治療促進剤、及び医薬組成物
US20250114455A1 (en)	2025-04-10	Radiosensitizing compositions and methods of use thereof